PHARMACEUTICAL IP

  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team

Fractional IP counsel for biotech: what to look for in a fractional IP adviser

  • Technology: Biotechnology, Pharmaceuticals
  • 16th November 2026
What to look for in part-time senior IP support for a growing biotech, from Series A to partnering and acquisition, and how experienced fractional IP counsel can help at every stage.
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image

In most early-stage biotechs, IP belongs to whoever has time for it. Usually that is the CEO or the CSO, with an outside patent firm handling the filings. It works well enough until investors, partners or acquirers start asking detailed questions about the portfolio, and by then some of the important decisions have already been made. More companies are now bringing in a senior IP professional part time to fill the gap. You will see this called fractional IP counsel, a fractional IP adviser (or advisor) or a fractional head of IP, and the names are used loosely. What matters more is what the person actually does: advise from outside, or step into the role.

Who is making the IP decisions?

A young biotech approaching its Series A might have one patent family, often licensed from a university, and perhaps two or three follow-on applications. A clinical-stage company raising a Series B or C will have considerably more. The science is moving quickly and the team wants to publish and present. Each conference abstract is an IP decision. So is each new filing, each choice about what to keep as know-how, and the question of which claims a future partner will actually care about.

Hiring a full-time head of IP often doesn’t make sense until the pipeline is big enough to justify it. Someone senior with UK pharma experience will cost well into six figures, and there may not be a full week’s work for them. The patent firm does what it is asked to do, but it doesn’t see the board papers or know that a partnering conversation starts next quarter. The founders are trying to run the science whilst raising money. Things get decided by default.

Investors, partners and acquirers will all look at the IP closely nonetheless. It sits at the centre of any biotech deal, and whatever IP strategy the company has before a funding round, a partnership or an acquisition is the one it will be explaining in diligence.

Fractional IP adviser or head of IP?

There is a difference between someone who advises on IP and someone who is responsible for it. An adviser gives a view when asked. A head of IP sets the strategy, goes to the management meetings and makes sure the work gets done.

Independent IP consultants can be very good at the first of these, but they usually work alone, so the execution has to go somewhere else. Patent firms are set up to do the execution, one instruction at a time, without being part of the management team.

Our fractional IP counsel service is meant to cover both. One of our patent directors works as the company’s head of IP for an agreed number of days a month. They own the strategy, join the relevant meetings, and are the person the scientists ring with a question. When something needs doing, our paralegals, docketing team and document systems are there to do it, along with the AI tools we have built for this work. We have no reason to recommend work the company doesn’t need.

If you have been looking for a fractional IP adviser, the quality of the advice is what matters most. Our patent directors have spent years in-house at pharma and biotech companies and have advised on IP strategy at every stage, from the first filing to life-cycle management. That experience means our advice is practical, commercially grounded and built around what investors and partners will actually look for. Whether you need a second opinion on a single question, regular strategic advice or someone to take full responsibility for the portfolio, we can help. We are always happy to talk through what would suit you.

Having sat on the other side of the table

Our patent directors have held senior in-house IP roles at global pharma companies and at biotechs. We have carried out due diligence and IP reviews for pharma companies looking to in-license and acquire biotech assets, so we know what they look for. We have seen what makes a buyer comfortable with a portfolio and what makes them hesitate. We have also had to live with those deals for years afterwards. That is the experience we bring to a biotech’s IP strategy, well before any partner is in the room.

The science and the industry specifics of your sector matter too. A small molecule needs a different IP strategy from an antibody or a cell therapy, and oncology and autoimmune programmes generally need quite different approaches. Pharma and biotech IP is a discipline of its own, and it is the only thing we do. We work as a team, so a client with one named director still has the rest of us to draw on.

The day-to-day work

A lot of the job is routine, and that is the part an outside firm usually never sees. Publication review is a good example. Every abstract, poster and paper needs checking before it goes out, so that nothing is disclosed before it is filed. It takes a great deal of time. We use Franklin, a publication review and invention spotting tool we built ourselves, and an attorney checks everything it produces. It regularly picks up inventions nobody had thought to report.

The rest is keeping the portfolio in step with the programme as it changes, watching what competitors are filing and publishing, reporting to the board, and helping scientists understand when and how to disclose an invention and why confidentiality matters.

On freedom to operate (FTO), our view is that an early-stage company rarely needs a full, expensive FTO report. It needs someone who knows the landscape well enough to spot the patents that matter, and who can do a fuller analysis when a programme or a deal calls for one. We use our Ammonite Chart software to show the landscape in a form boards and investors can follow.

All of our AI use is covered by our professional obligations as patent attorneys. Client material is not used to train models and is not retained.

When the deal comes

If the portfolio has been reviewed and the validity risks identified in advance, diligence is far less painful. Fractional IP counsel can prepare the company for it, negotiate the IP terms of a licence or collaboration, and explain the IP position to the board and investors. For the diligence work itself we use Cassandra, our own due diligence and contract review tool, and an attorney checks everything it produces.

As the company moves into the clinic, the role picks up global filing strategy, regulatory exclusivities such as SPCs and orphan and paediatric exclusivity, and life-cycle management. We dealt with all of these in-house.

How it works in practice

We work flexibly, according to your needs. We agree a number of days a month to start with, and you only pay for the days you use. That might be a light commitment whilst the portfolio is small, more around a funding round, a partnering deal or a busy period of filing, and less again afterwards. We can review the arrangement regularly, and there is no minimum term.

We can work remotely or come in to see the team, whichever suits you. Most engagements start within a few weeks with a portfolio review and a strategy session, and the shape of the work follows from there.

We can take on the drafting and prosecution too, so that the strategy and the work sit with one team.

Where a company already has a head of IP, we can work alongside them, providing cover for leave, extra capacity or a second senior opinion for as long as they need it. They get access to our AI tools as well.

Evolve AI
Fractional IP counsel

Related insights...

Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

The enablement paradox and the danger of definitions (Wyeth v AstraZeneca)

  • 6th October 2026
The Federal Circuit’s decision in Wyeth v AstraZeneca (No. 2024-2325) applied the enablement test to a dose invention. The case is an interesting contrast to the other recent case to apply enablement to a method of treatment claim, Teva v Eli Lilly.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.

When do you file for a drug combination invention? (T 592/24)

  • 16th July 2026
Drug combination inventions are increasingly difficult to protect. File too early for a drug-combination invention and the application may lack the data to support the non-obvious effect of the combination. Wait for the trial read-out, and a competitor, or your own published protocol, may have already placed the invention in the public domain. 
Stack of gold slabs with a glowing turquoise middle layer on dark blue, Evolve abstract article image.
Stack of gold slabs with a glowing turquoise middle layer on dark blue, Evolve abstract article image.

Patenting the use of medical devices (T 0941/24)

  • 26th June 2026
Patenting medical devices in Europe is challenging. First, there is the problem that medical use claims are not permitted for medical devices, whilst simultaneously methods of treatment or surgery using a device are excluded from patentability. 
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

Mechanistic insights supporting the sufficiency and inventive step of a therapeutic use (without clinical data) (T 1601/22)

  • 24th February 2026
At the EPO, it is perfectly possible for a therapeutic invention to survive without clinical data. The recent decision in T 1601/22 confirmed this sometimes surprisingly low bar for sufficiency in Europe for therapeutic inventions.
Gold ball-and-stick molecule with one turquoise atom on dark blue, Evolve pharmaceuticals image
Gold ball-and-stick molecule with one turquoise atom on dark blue, Evolve pharmaceuticals image

EPO pharma case law trends 2025: Clinical inventions

  • 26th November 2025
The law in the pharma sector is also constantly evolving. Understanding the case law trends when drafting, prosecuting and defending these cases is therefore paramount. In our second post on EPO pharma case law trends in 2025, we review the most impactful decisions of the year relating to clinical-stage inventions. 
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

Insufficiency resulting from mutually exclusive definitions: The repercussive effect of dependent claims (T 0878/23)

  • 18th November 2025
In T 0878/23, the Board of Appeal ruled that mutually exclusive ranges in dependent claims constitute fatal insufficiency rather than a mere lack of clarity. This decision underscores the “repercussive effect” of claim dependencies, warning that internal contradictions can make an invention technically impossible to perform.
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image

Sufficiency at the priority date: A study protocol is not “the same” as a therapeutic effect invention (T 0883/23)

  • 31st October 2025
Therapeutic inventions are generally not considered sufficiently disclosed absent supporting data. The recent decision in T 0883/23 found that this applies both at the priority date and the filing date of the patent.
Single cut gold stone glowing turquoise at its heart on dark blue, Evolve abstract article image
Single cut gold stone glowing turquoise at its heart on dark blue, Evolve abstract article image

Patentee’s own post-published data undermines the credibility of their broad cat antibody patent (T 0709/23)

  • 27th October 2025
How early is too early to file a biotech patent? EPO decision T 0709/23 provides a costly answer, demonstrating the fatal risks of claiming a broad therapeutic use before the link between structure, function, and actual effect is truly understood.
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image

From oil to gemstones: Our shifting understanding of the value of data

  • 10th October 2025
The concept of data as oil has been around for a number of years, but does the analogy still hold? In the pharma and biotech industry, there is now a shift away from thinking of data as a bulk commodity of raw material, towards the pursuit of high quality data that can improve the performance…
Sphere of gold hexagon plates with glowing turquoise seams on dark blue, Evolve abstract article image.
Sphere of gold hexagon plates with glowing turquoise seams on dark blue, Evolve abstract article image.

An “immunogenic composition” is not a vaccine (T 0070/23)

  • 8th August 2025
While G1/24 mandates consulting the description, T 0070/23 is a crucial reminder of its limits. The case shows how the Board of Appeal refused to let a description definition override the clear technical meaning of a product claim.
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice
  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice